IL2 and neoplasm: While the adoptive transfer of tumor-infiltrating lymphocytes (TILs), harvested from the tumor, has demonstrated feasibility when administered with IL-2 following chemoradiotherapy in patients with locally advanced NPC, the contribution of TILs to the overall clinical activity is difficult to determine [75].